The global life sciences industry continues to face periods of uncertainty, with mounting pressures experienced across the sector.
We look at issues such as increased regulation, dialogue on personalised healthcare programmes, the ubiquitous need to innovate and pricing pressures on an already challenged industry by those that end up paying the bill.
In addition, the UK industry is having to tackle mounting challenges and competition from around the world as countries like India emerge. Our industry specialists from across Deloitte provide an extensive depth of knowledge on the range of current issues experienced by the pharmaceuticals, biotechnology, medical device and private healthcare industries.
|Deloitte Centre for Health Solutions’ new report discusses the need to provide more effective and compassionate care at the end-of-life. It covers: the current state of end-of-life care, the challenges that need to be addressed and the potential solutions for transforming end-of-life care for all. Read the full report|
|Financial Times/Deloitte Pharmaceutical & Biotechnology Conference 2014
Predictions 2020 - The future of the industry. Discover more
|Deloitte named Corporate Financier of the Year by HealthInvestor for second consecutive year|
|2014 Global life sciences sector outlook|
|2014 Global health care sector outlook|
Thoughts from the centre
Read our blog.